RCM
BPMC

Riverhead Capital Management’s Blueprint Medicines BPMC Stock Holding History

Riverhead Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$10K Hold
136
– – ﹤0.01% 1488
2019
Q2 		$13K Buy
+136
New +$11.2K ﹤0.01% 1506

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Riverhead Capital Management's BPMC Position: Q3 2019 in Review

Riverhead Capital Management held its Blueprint Medicines (BPMC) position steady in Q3 2019 at 136 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #1488.

Riverhead Capital Management first reported a position in BPMC in Q2 2019 and has held it in 2 quarters since. The position peaked at $13K in Q2 2019. 220 funds tracked by Wall St. Rank hold BPMC as of Q3 2019.

  • Riverhead Capital Management held 136 shares of Blueprint Medicines worth $10K as of Q3 2019.
  • Riverhead Capital Management left its Blueprint Medicines share count unchanged in Q3 2019.
  • Blueprint Medicines made up ﹤0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1488 holding.
  • Riverhead Capital Management first reported a position in Blueprint Medicines in Q2 2019 and has held it in 2 quarters since.
  • Riverhead Capital Management's Blueprint Medicines position peaked at $13K in Q2 2019.
  • 220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.